IRB #

STUDY00020600

Title

A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

Principal Investigator

Emerson Chen

Study Purpose

The purpose of this study is to compare pembrolizumab to placebo in participants with esophageal carcinoma that are also receiving chemoradiotherapy.

Medical Condition(s)

Esophageal
Esophageal Carcinoma

Eligibility Criteria

Inclusion
-At least 18 years of age
-Deemed suitable for definitive chemoradiotherapy

Exclusion
-Has had weight loss of >20% in the previous 3 months
-Has had prior chemotherapy or RT for esophageal cancer

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

5 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Merck

Recruitment End

10/01/2024

Compensation Provided

No


Go Back